CAR T-cells in vivo could transform cancer care
Relevance:
GS Paper III – Science & Technology
CAR T-cell Therapy
- CAR (Chimeric Antigen Receptor) T-cell therapy: Genetically engineers a patient’s T-cells to recognise and destroy cancer cells.
- Targets proteins (e.g., CD19, CD20) on B-cells responsible for cancers like leukaemia and lymphoma.
- Traditionally involves:
- Ex vivo T-cell extraction
- Viral vector-based modification
- Lymphodepleting chemotherapy
- Cost: ₹60–70 lakh per patient in India
New Breakthrough: In-vivo CAR T-cell Engineering
- Published in Science, June 19, 2025.
- Key innovation: No need to extract and modify T-cells in a lab.
- Instead, mRNA + Lipid Nanoparticles (LNPs) injected directly into the body:
- LNPs carry genetic instructions for CAR.
- Targeting via CD8+ antibodies ensures only cytotoxic T-cells are modified.
- Temporary CAR expression reduces risk of long-term genetic changes.
Results in Animal Models
- Mice: Tumours regressed; B-cells destroyed.
- Monkeys:
- Up to 85% CD8+ T-cells converted into CAR T-cells.
- B-cells depleted from lymph nodes, spleen, bone marrow.
- No chemotherapy or viral vectors required.
Advantages Over Traditional Method
- No lab-based manufacturing (ex vivo)
- No chemotherapy-based lymphodepletion
- Lowered risk of permanent side effects
- Biodegradable Lipid 829 improves safety and liver tolerance
- Infusion-based dosing similar to a drug, not a complex procedure
Risks and Limitations
- One monkey developed Hemophagocytic Lymphohistiocytosis (HLH) → severe immune reaction.
- Safety in humans is unproven; clinical trials essential.
- Scalability and reproducibility still major concerns, especially during mass production.
Use Beyond Cancer: Autoimmune Diseases
- Potential use in Lupus, Myositis, and other B cell-mediated diseases.
- Reprogrammed T-cells wiped out malfunctioning B-cells → replaced by naïve B-cells.
- May help reset immune system without long-term immunosuppression.
India-Specific Relevance
- High burden of B-cell cancers: DLBCL, Follicular lymphoma, ALL (75% childhood cancer cases).
- Rising autoimmune disorders post-COVID (30% rise).
- In-vivo technique:
- Cheaper, easier to administer, requires less infrastructure.
- Suitable for rural/semi-urban settings lacking CAR T-cell labs.
- Could democratise access to advanced immunotherapies.
Conclusion (Short)
- The new in-vivo CAR T-cell technique offers a promising, safer, and more accessible alternative to conventional therapy by eliminating the need for complex lab procedures and chemotherapy. If proven safe in humans, it could revolutionise cancer and autoimmune treatment, especially in resource-limited settings like India.
UPSC Practice Questions
Q1. What is CAR T-cell therapy? Discuss recent advances in CAR T-cell technology and their significance for countries like India. (250 words)
Q2. Examine the role of mRNA and lipid nanoparticle-based platforms in transforming cancer immunotherapy. (150 words)
Q3. With reference to CAR T-cell therapy, compare and contrast ex vivo and in vivo methods of T-cell modification. (10 marks)
Prelims MCQs
Q1. With reference to CAR T-cell therapy, which of the following statements is/are correct?
- It is used to treat only autoimmune diseases.
- It involves modifying T-cells to express synthetic receptors that target cancerous B-cells.
- In-vivo CAR T-cell therapy eliminates the need for chemotherapy.
Select the correct answer using the codes below:
A. 1 and 2 only
B. 2 and 3 only ✅
C. 1 and 3 only
D. 1, 2, and 3
